Brief: Adaptive Biotechnologies Receives Expanded Medicare Coverage Of Clonoseq For Assessing Measurable Residual Disease In Mantle Cell Lymphoma
07/11/2024 12:57
Nov 7 (Reuters) - Adaptive Biotechnologies Corp
ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES RECEIVES EXPANDED MEDICARE
COVERAGE OF
CLONOSEQ® FOR ASSESSING MEASURABLE RESIDUAL DISEASE IN MANTLE
CELL LYMPHOMA
Source text: ID:nGNX7qpZg0
Further company coverage: ADPT.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Adaptive Biotechnologies
See all newsBrief: Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile